T A Glauser1, P O Clark, K McGee. 1. Children's Comprehensive Epilepsy Program, Department of Neurology, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. glauser@chmcc.org
Abstract
PURPOSE: The long-term effectiveness of topiramate (TPM) was evaluated in children with West syndrome previously refractory to antiepileptic drug (AED) therapy. METHODS: Children with infantile spasms who completed a pilot study were eligible to enter a long-term extension phase in which the dosages of TPM and other AEDs could be adjusted to optimal response (maximum, 50 mg/kg/day TPM). The mean duration of long-term therapy was 18 months in the 11 children who were followed; the mean TPM dosage was 29 mg/kg/day. RESULTS: Eight (73%) children were continuing TPM therapy at the time data were analyzed; four (50%) children were spasm free, seven (88%) had experienced a > or =50% reduction in spasms, and three (38%) were able to achieve TPM monotherapy. CONCLUSIONS: TPM was well tolerated in that no patients discontinued because of adverse events. The response achieved with TPM during the pilot study was maintained in most children.
PURPOSE: The long-term effectiveness of topiramate (TPM) was evaluated in children with West syndrome previously refractory to antiepileptic drug (AED) therapy. METHODS:Children with infantile spasms who completed a pilot study were eligible to enter a long-term extension phase in which the dosages of TPM and other AEDs could be adjusted to optimal response (maximum, 50 mg/kg/day TPM). The mean duration of long-term therapy was 18 months in the 11 children who were followed; the mean TPM dosage was 29 mg/kg/day. RESULTS: Eight (73%) children were continuing TPM therapy at the time data were analyzed; four (50%) children were spasm free, seven (88%) had experienced a > or =50% reduction in spasms, and three (38%) were able to achieve TPM monotherapy. CONCLUSIONS:TPM was well tolerated in that no patients discontinued because of adverse events. The response achieved with TPM during the pilot study was maintained in most children.
Authors: Kelly G Knupp; Erin Leister; Jason Coryell; Katherine C Nickels; Nicole Ryan; Elizabeth Juarez-Colunga; William D Gaillard; John R Mytinger; Anne T Berg; John Millichap; Douglas R Nordli; Sucheta Joshi; Renée A Shellhaas; Tobias Loddenkemper; Dennis Dlugos; Elaine Wirrell; Joseph Sullivan; Adam L Hartman; Eric H Kossoff; Zachary M Grinspan; Lorie Hamikawa Journal: Epilepsia Date: 2016-09-12 Impact factor: 5.864
Authors: M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead Journal: Neurology Date: 2004-05-25 Impact factor: 9.910